Literature DB >> 19594

Biochemical differentiation of amphetamine vs methylphenidate and nomifensine in rats.

C Braestrup.   

Abstract

Amphetamine-like stimulants were divided into two groups, one in which the stereotyped behaviour was not antagonized by reserpine [(+)-amphetamine, (-)-amphetamine, methamphetamine, phenmetrazine and phenethylamine] and another group in which the behavioural effects were blocked by reserpine (methylphenidate, nomifensine, pipradrol and amfonelic acid (NCA; Win 25978)). Both groups increased homovanillic acid (HVA) in whole brain 2 h after administration. The 'methylphenidate group' also increased brain 3,4-dihydroxyphenylacetic acid (DOPAC) in naive rats; whereas the '(+)-amphetamine group' decreased DOPAC in naive rats, as well as in reserpinized rats, alpha-methyl-p-tyrosine-treated rats and after acute hemisection. The reserpine antagonism of the 'methylphenidate group'-induced stereotyped behaviour was partially reversed by type A monoamine oxidase inhibition. The '(+)-amphetamine group'-induced stereotyped behaviour was not blocked by short time pretreatment with alpha-methyltyrosine, only by longer pretreatment intervals. The mechanisms by which the two groups are differentiated biochemically is discussed with special attention to possible intra-neuronal inhibition of dopamine oxidation by the '(+)-amphetamine group'.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 19594     DOI: 10.1111/j.2042-7158.1977.tb11370.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  11 in total

1.  Proceedings of the British Pharmacological Society. London, 17th-19th December, 1984. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1985-03       Impact factor: 8.739

2.  Monoamine oxidase inhibition by (+)-amphetamine in vivo [proceedings].

Authors:  D E Clarke; H H Miller; P A Shore
Journal:  Br J Pharmacol       Date:  1979-07       Impact factor: 8.739

3.  "Designer" amphetamines: effects on behavior and monoamines with or without reserpine and/or alpha-methyl-para-tyrosine pretreatment.

Authors:  M T Martin-Iverson; N Yamada; A W By; B A Lodge
Journal:  J Psychiatry Neurosci       Date:  1991-12       Impact factor: 6.186

4.  3-Methoxytyramine: its suitability as an indicator of synaptic dopamine release.

Authors:  P C Waldmeier; J Lauber; W Blum; W J Richter
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1981-01       Impact factor: 3.000

5.  A comparison of the effects of sibutramine hydrochloride, bupropion and methamphetamine on dopaminergic function: evidence that dopamine is not a pharmacological target for sibutramine.

Authors:  D J Heal; A T Frankland; J Gosden; L J Hutchins; M R Prow; G P Luscombe; W R Buckett
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  Effect of chronic amphetamine administration on central dopaminergic mechanisms in the vervet.

Authors:  F Owen; H F Baker; R M Ridley; A J Cross; T J Crow
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  Evidence for monoaminergic involvement in triadimefon-induced hyperactivity.

Authors:  K M Crofton; V M Boncek; R C MacPhail
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain.

Authors:  F Karoum; S J Chrapusta; R Brinjak; A Hitri; R J Wyatt
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

9.  Acute effects of sigma ligands on the extracellular DOPAC level in rat frontal cortex and striatum.

Authors:  K Matsuno; K H Matsunaga; S Mita
Journal:  Neurochem Res       Date:  1995-02       Impact factor: 3.996

10.  The effects of amfonelic acid and some other central stimulants on mouse striatal tyramine, dopamine and homovanillic acid.

Authors:  A V Juorio
Journal:  Br J Pharmacol       Date:  1982-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.